Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, discusses potential applications of CXCR4 inhibitors and outlines the benefits of using CXCR4 as a therapeutic target for mycosis fungoides (MF). Whilst CXCR4 antagonists are approved by the FDA for stem cell mobilization, they have been found to induce apoptosis of malignant cells through inhibition of downstream signaling cascades involved in cell survival. Therefore, several ongoing pre-clinical and clinical trials are investigating CXCR4 antagonists in combination with other agents and as a monotherapy in solid tumors. Dr Moyal explains that CXCR4 inhibition strategies might be more efficient in MF than in other tumors because it can be used as a localized skin-directed treatment. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.